ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Comparison of the effectiveness of pirfenidone and nintedanib in patients with advanced stage idiopathic pulmonary fibrosis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic value of baseline serum KL-6 for mortality risk in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy: A retrospective cohort study.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimIdiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disease with high mortality, especially in advanced stages, defined as forced vital capacity (FVC) ≤50% and/or diffusing capacity of the lungs for carbon monoxide (DLCO) ≤30% of predicted values. While antifibrotic therapies, such as nintedanib and pirfenidone, are effective in mild to moderate IPF, their efficacy in advanced-stage IPF remains unclear due to the exclusion of these patients from major clinical trials. This study aimed to compare the effectiveness of nintedanib and pirfenidone on mortality and to identify predictors of mortality in patients with advanced-stage IPF.
methodsThis retrospective cohort study included 198 advanced-stage IPF patients treated with nintedanib (n=91) or pirfenidone (n=107) between 2017 and 2023. Demographic, clinical, and radiological data were collected. Mortality predictors were analyzed using multivariate Cox regression, and survival outcomes were compared using adjusted Kaplan-Meier curves.
resultsIndependent predictors of mortality were found to be six-minute walk distance (HR=0.99, 95% CI: 0.996-0.999, p=0.049), pulmonary fibrosis score ≥150 (HR=1.86, 95% CI: 1.07-3.22, p=0.026), and heart failure (HR=2.24, 95% CI: 1.18-4.26, p=0.014). After adjusting for these factors, no significant differences in mortality were observed between the nintedanib and pirfenidone groups.
conclusionsNintedanib and pirfenidone showed comparable effectiveness in reducing mortality among advanced-stage IPF patients. Future clinical trials should include advanced-stage patients to better evaluate treatment efficacy in this population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.